Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q

被引：20
|
作者：
Starczynowski, Daniel T.
Karsan, Aly [1 ]
机构：
[1] BC Canc Agcy, Genome Sci Ctr, Vancouver, BC, Canada
来源：
CELL CYCLE | 2010年 / 9卷 / 05期
基金：
加拿大健康研究院;
关键词：
innate immunity; myelodysplastic syndromes; RPS14; FLI1; microRNAs; NF kappa B; IDENTIFICATION; 5Q-SYNDROME;
D O I：
10.4161/cc.9.5.11156
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：855 / 856
页数：2
相关论文
共 50 条
  • [21] Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH
    Evers, Christina
    Beier, Manfred
    Poelitz, Anne
    Hildebrandt, Barbara
    Servan, Kati
    Drechsler, Matthias
    Germing, Ulrich
    Royer, Hans-Dieter
    Royer-Pokora, Brigitte
    GENES CHROMOSOMES & CANCER, 2007, 46 (12): : 1119 - 1128
  • [22] 5q deletion myelodysplastic syndrome
    Chari, Preethi S.
    Chander, Smitha
    Sundareshan, T. S.
    Prasad, Sujay
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2017, 60 (02) : 301 - +
  • [23] Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion
    Ximeri, Maria
    Galanopoulos, Athanasios
    Klaus, Mirjam
    Parcharidou, Agapi
    Giannikou, Krinio
    Psyllaki, Maria
    Symeonidis, Argyrios
    Pappa, Vasiliki
    Kartasis, Zafiris
    Liapi, Dimitra
    Hatzimichael, Eleftheria
    Kokoris, Styliani
    Korkolopoulou, Penelope
    Sambani, Constantina
    Pontikoglou, Charalampos
    Papadaki, Helen A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (03): : 406 - 414
  • [24] Innate Immune Signaling in the Myelodysplastic Syndromes
    Starczynowski, Daniel T.
    Karsan, Aly
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (02) : 343 - +
  • [25] TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion
    Montoro Gomez, Maria Julia
    Palomo, Laura
    Vidal, Pablo
    Fuster-Tormo, Francisco
    Such, Esperanza
    Ortega, Margarita
    Gonzalez, Teresa
    Lopez-Cadenas, Felix
    Garcia-Avila, Sara
    Garcia-Gisbert, Nieves
    Mora Castera, Elvira
    Rivero, Eugenia
    Bosch, Francesc
    Jerez, Andres
    Diez-Campelo, Maria
    Sole, Francesc
    Valcarcel, David
    BLOOD, 2022, 140 : 6949 - 6951
  • [26] Myelodysplastic syndromes (MDS) with a deletion 5q display a specific immunophenotypic profile
    Oelschlaegel, U.
    Westers, T. M.
    Mohr, B.
    Parmentier, S.
    Sockel, K.
    Bornhaeuser, M.
    Van de Loosdrecht, A. A.
    Platzbecker, U.
    LEUKEMIA RESEARCH, 2013, 37 : S47 - S48
  • [27] Errant innate immune signaling in del(5q) MDS
    Starczynowski, Daniel T.
    BLOOD, 2014, 124 (05) : 669 - 671
  • [28] Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion
    Duong, Vu H.
    Komrokji, Rami S.
    List, Alan F.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (02) : 105 - 116
  • [29] High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide
    Jonasova, Anna T.
    Polak, Jaroslav
    Vostry, Martin
    Kostecka, Arnost
    Bokorova, Radka
    Neuwirtova, Radana
    Siskova, Magda
    Caniga, Miroslav
    Sponerova, Dana
    Cermak, Jaroslav
    Mikulenkova, Dana
    Brezinova, Jana
    Michalova, Kyra
    Fuchs, Ota
    BLOOD, 2013, 122 (21)
  • [30] A paediatric myelodysplastic syndrome with 5q deletion associated with Fanconi anaemia
    Kornreich, Laure
    Soulier, Jean
    Grange, Beatrice
    Girard, Sandrine
    Ouchee-Chardin, Marie
    Ceraulo, Antony
    PEDIATRIC BLOOD & CANCER, 2020, 67 (07)
12345